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Abstract Reduced turn-over of tau by caipains is a possible 
mechanism to facilitate the incorporation into paired helical fila- 
ments (PHFs) in Alzheimer's disease. The present study shows 
that the differently phosphorylated fetal tan isoforms are all 
rapidly proteolysed to an equal extent by human brain m-calpain. 
This result argues against the hypothesis that this type of fetal 
phosphorylation is involved in reducing tau turn-over by calpain 
in Alzheimer's disease. Adult and fetal tau fragments in vitro 
generated by m-calpain, but not trypsin, cathepsin D or chymo- 
trypsin resemble the post-mortem in situ degradation patterns, 
suggesting a possible role for calpains in tau metabolism in vivo. 
Tau incorporated into PHFs was considerably more resistant o 
proteolysis by calpain which can help to explain the persistence 
of these structures in Alzheimer's disease. 
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1. Introduction 
Dysregulation of Ca 2+ homeostasis i considered a possibly 
important factor in neuronal degeneration but little is known 
about the precise mechanisms involved. The pathway may in- 
clude dysregulation of proteolysis by the calpain system. Ab- 
normally high levels of activated isoforms of/.t-calpain [1] and 
reduced endogenous calpain inhibitor (calpastatin) [2,3] levels 
have been measured in the brains of patients with Alzheimer 
disease, lntracellular neurofibrillary tangles are a neuropathol- 
ogical hallmark in Alzheimer's disease and the presence of these 
lesions shows a high correlation with the development of clini- 
cal symptoms of dementia [4,5]. Major progress is made in the 
biochemical characterization of the paired helical filaments 
(PHFs), the ultrastructural components of the neurofibrillary 
degeneration. It is now generally accepted that the major pro- 
tein component in these structures is the microtubule-associ- 
ated protein tau in a state of hyperphosphorylation (for review 
see [69]). Antibodies produced against phosphorylation-de- 
pendent epitopes on PHF-tau [10 12] and mass spectroscopy 
on isolated peptides [13,14] have shown that fetal and PHF tau 
isoforms share many phosphorylated sites. Previous studies 
showed that tau is a substrate for the CaZ+-dependent neutral 
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protease [15] and the sensitivity to calpain of differently 
phosphorylated tau isoforms has been shown to vary [16]. 
In this study we investigated the hypothesis that fetal type 
phosphorylation reduces the turn-over ate of tau by calpain 
and might, therefore, represent a mechanism for the accumula- 
tion of tau in PHFs. We also studied the degradation pattern 
generated in vitro by m-calpain from fetal and adult tau 
isoforms in comparison to proteolytic tau fragments present in 
post-mortem brain in an effort to provide more evidence for the 
possible involvement of calpains in tau metabolism. Finally, we 
examined the differential sensitivity to calpains in mixtures of 
fetal and adult tau with PHF-tau. 
2. Materials and methods 
2.1. Protein preparations 
The affinity-purified human tau and the polyclonal anti-tau antise- 
rum (JM) was prepared as described elsewhere [17], except hat the 
tau-1 monoclonal ntibody was used for the preparation of the affinity 
column. Heat-stable fetal (22 weeks of gestation) brain extract (0.15 
g/ml) for use in the calpain assay was prepared in Tris/saline, pH 7.4, 
containing 1% Triton X-100 and 1 mM EGTA. For the preparation of 
enriched PHF-tau fractions, cerebral cortex from post-mortem Alz- 
heimer brain was homogenized (2 g/20 ml) in 10 mM Tris, pH 7.4, 
0.8 M NaCI, 1 mM EGTA, 10% sucrose and centrifuged at 27,000 x g. 
The supernatant was incubated for 2 h at 37°C with addition of 1% 
mercaptoethanol and 1% N-lauroylsarcosine or 1% Triton X-100 and 
centrifuged at 100,000 x g for 120 min. The pellet was then rinsed and 
resuspended in Tris/saline, pH 7.4. Human m-calpain was purified from 
postmortem cerebral cortex by a procedure involving chromatography 
on DEAE-cellulose, phenyl-Sepharose, Ultrogel AcA-44, and DEAE- 
Biogel A as described [18]. Human post-mortem normal and AD brains 
were provided by the McLean Hospital Brain Tissue Center. 
2.2. Electrophoresis and blotting 
All aliquots were run on 10% SDS-PAGE minigels and blotted to 
nitrocellulose. Tau proteins were detected using the polyclonal rabbit 
anti-tau antiserum (JM) at a dilution of 1/2000. Densitometric analysis 
was performed using an Color OneScanner (Apple) and Scan Analysis 
Software. 
2.3. Protease assays 
For proteolysis with calpain, trypsin and chymotrypsin, the tau prep- 
arations were incubated at 30°C in a buffer containing 50 mM Tris 
(pH 7.5), 100 mM NaCI, 1 mM EDTA, 2 mM DTT and 5 mM CaC1. 
Cathepsin D was used in 0.1 M NaAc, 1 M NaC1 at pH 3.8. The 
calpain/tau molar ratio was 1 : 10 when heat-stable tau extracts were 
examined or tau and PHF-tau degradation were compared and 1 : 100 
when only purified adult tau was used. Cathepsin D was used at a 
tau/enzyme ratio of 1:20 and trypsin and chymotrypsin at a ratio of 
1 : 100. Proteolysis was stopped by adding an equal volume of 2 x SDS- 
Laemmli Sample buffer [19] to aliquots of the reaction mixture removed 
taken at the different ime points and boiling for 5 min. 
Cathepsin D (human liver) wa~p~rchased from Athens Research and 
Technology Inc., Athens, GA. Tr'y,p'sin (bovine pancreas) and chymo- 
trypsin (bovine pancreas, Type VII)"~ere purchased from Sigma, St. 
Louis, MO. 
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Fig. 1. Tau immunoblot analysis howing the different sensitivity of fetal tau isoforms and PHF-tau to degradation by m-calpain. (A) Heat-stable 
fetal brain extract. (B) Mixture of heat-stable f tal brain extract and PHFs. (C) PHFs. The indications for molecular weight markers are 64 kDa, 
50 kDa, 36 kDa and 30 kDa. Panel D shows the densitometric analyses of tau immunoblots ofmixtures of heat-stable f tal brain extract and PHF 
as shown in C. Intact proteins (fetal tau (m), PHF-tau (A)) and breakdown products (30 kDa (<>), 36 kDa (©)) were plotted as a percentage of their 
starting concentration (fetal tau and PHF-tau values on the left y-axis; 30 kDa and 36 kDa values on the right y-axis). The data in the graph represent 
the mean values obtained from duplicate xperiments. Notice the decrease for fetal tau to 5% of its starting value and an increase to over 1000% 
for the 30 kDa breakdown products. 
3. Results 
Tau isoforms in heat-stable xtracts from fetal brain at 22 
weeks of gestation were rapidly degraded by m-calpain (Fig. 
1A). The polyclonal antibody that was used for immunodetec- 
tion of tau reacts with tau isoforms independent of their state 
of phosphorylation and shows how the multiple tau bands, 
representing different phosphorylation states of the single tau 
isoform expressed in fetal brain, were hydrolysed by m-calpain 
at a similar rate. Several major degradation products generated 
by m-calpain could be identified, especially at short incubation 
times (Fig. 1A). The proteolytic fragments, which included 
those with apparent molecular weights of approximately 30 and 
36 kDa, were already present at lower concentrations in the 
heat-treated extracts before the addition of calpain or Ca 2÷. 
Because these heat-treated brain extracts were prepared in the 
presence of EGTA sufficient o block endogenous Ca:+-medi - 
ated proteolysis during the preparation of the sample, the re- 
sults indicate that calpain is also active on tau in situ. We next 
examined the activity of m-calpain toward tau isoforms in a 
mixture containing an enriched PHF preparation and heat- 
treated fetal brain extract (Fig. 1B). At a calpain concentration 
resulting in a rapid degradation of fetal tau isoforms, the PHF- 
tau in the mixture (Fig. 1 B) or by itself (Fig. 1 C) was almost 
completely protected from degradation. To rule out the possi- 
bility that N-lauroylsarcosine was responsible for protecting 
PHF from degradation, we also used PHFs that were prepared 
with Triton X-100 and found the same results. Triton X-100 
was also present in the heat-stable extracts and did not inhibit 
the degradation of fetal tau. Densitometric analysis of the tau 
band intensities, expressed as percentages of the initial concen- 
trations of tau in untreated extracts, demonstrates that the 
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Fig. 2. Tau immunoblot analysis howing the different sensitivity of adult au isoforms and PHF-tau to degradation by m-calpain. (A) Adult tau. 
(B) Mixture of adult tau and PHFs. (C) PHFs. The indications for molecular weight markers are 64 kDa, 50 kDa, 36 kDa and 30 kDa. 
30 kDa and 36 kDa tau breakdown products were increased l0 
and 2.5 times, respectively, after 5 min incubation (Fig. 1D). In 
the same experiment the values for full-size fetal tau were de- 
creased to 5% of their original density, while the values for the 
PHF-tau bands were unchanged. 
A similar m-calpain experiment performed on a mixture of 
PHFs and purified adult human tau is shown in Fig. 2. Com- 
pared to soluble adult tau, the PHFs were considerably more 
resistant to proteolysis by calpains as observed in the earlier 
experiments. Several breakdown product, generated by m-cal- 
pain from adult tau, including bands at 30K and 36K, were 
similar in size to those detected before calcium was added to 
the incubation mixture. 
In Fig. 3 the pattern of human adult tau degradation gener- 
ated by m-calpain was compared to that of other common 
proteases to investigate he specificity of the calpain in generat- 
ing fragments pre-existing in post-mortem brain samples. As 
shown in Fig. 3B and 3C, respectively, purified tau was rapidly 
degraded by trypsin and chymotrypsin but the complex mixture 
of breakdown products generated by each protease did not 
include persisting limited proteolytic fragments uch as those 
seen after calpain digestion. Cathepsin D generated two major 
tau degradation bands (Fig. 3D) but these differed from the tau 
breakdown products generated by calpain and the ones present 
in unincubated tau preparations. 
4. Discussion 
Our results indicate that fetal-type phosphorylation is not a 
significant factor in reducing the sensitivity of tau to proteolysis 
by human brain m-calpain. Previous reports [16] have shown 
that in vitro phosphorylation f bovine tau by cAMP-depend- 
ent protein kinase increased its resistant to calpain-mediated 
degradation. The same group recently also reported that phos- 
phorylation of the longest human tau isoform by the proline- 
directed kinase ERK1 had no effect [20]. Many of the phospho- 
rylation sites identified in PHF are proline-directed sites and 
were also shown to be phosphorylated, to a certain extent, in 
fetal tau [21]. However, several phosphorylated positions iden- 
tiffed in PHF-tau are not flanked by a proline and have 
not been detected in fetal tau [13,22]. Taken together, 
the data indicate that decreased susceptibility of hyperphos- 
phorylated tau to calpain may only result from site specific 
phosphorylation that is possibly not proline-directed and 
distinct from the phosphate groups present on tau in fetal 
brain. Among the possible candidate kinases for this process 
are the cAMP-dependent protein kinase, shown to render 
calpain resistance to tau in vitro [16] and glycogen syn- 
thase kinase fl, which can phosphorylate au in vitro at sites 
not flanked by a proline [23] and to an extent hat makes it shift 
in SDS to the PHF-tau position [24-26]. Another interesting 
candidate is a 35/41 kDa brain kinase, described by Biernat et 
al. [27] that phosphorylates tau in a non-proline-directed way 
and strongly affects its binding to microtubules. 
The low efficiency of calpain in degrading PHF's is not sur- 
prising in view of the reported high resistance of these struc- 
tures to proteases [28] and phosphatases [29] and most likely 
reflects inaccessibility o the enzymatic activity due to steric 
hindrance. Alternatively other modifications of PHP-tau, such 
as Maillard-reaction-related events may also confer protease 
resistance [30]. 
The calpains have been suggested as an efficient system to 
regulate the turn-over of cytoskeletal proteins [31,32] and the 
microtubule associated proteins MAPIA [33], MAP2 [34] and 
tau [15] are all good in vitro substrates. Our results show a 
remarkable similarity between the tau breakdown products 
generated with purified human brain m-calpain in vitro and the 
tau degradation products present in post-mortem brain. The 
post-mortem calpain-like tau degradation products detected in 
the first lane in Figs. 2A and 3A for adult tau and in the first 
lane of Fig. 1A for fetal tau are indeed generated in situ since 
all endogenous calpain activity was inactivated during the prep- 
aration of the samples by heat treatment and by the addition 
of 1 mM EGTA. Although this may indicate that some calpain 
is activated uring the postmortem interval, this event likely 
reflects a similar function in vivo. 
Altered calcium uptake was observed in vitro in fibroblasts 
isolated from aged individuals and Alzheimer patients [35] and 
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Fig. 3. Immunoblot showing the degradation ofpurified adult tau by different proteolytic enzymes. (A) m-calpain. (B) Trypsin. (C) Chymotrypsin. 
(D) Cathepsin D. The indications for molecular weight markers are 64 kDa, 50 kDa, 36 kDa and 30 kDa. Arrowheads inlane 4 of every blot indicate 
the corresponding positions for tau breakdown generated by m-calpain as shown in panel A. 
in vivo postmitotic neurons are likely to show the highest sus- 
ceptibility to an abnormal Ca 2+ metabolism. Increased levels of 
intracellular Ca 2+ will induce increased proteolysis by chronic 
calpain activation. Neurons may try to counteract the abnor- 
mally high turn-over of the cytoskeleton by altering its phos- 
phorylation state. It is reasonable toexpect hat some of these 
phosphorylation events, apparently distinct from those gener- 
ating the different fetal tau isoforms, could result in an unbal- 
anced decreased turn-over of tau by calpains [36] and also 
reduce the microtubule binding of tau [12,28,37,38]. 
A recent report by Matsuo et al. [39] has forced a reevalua- 
tion of the phosphorylation state of normal tau by demonstrat- 
ing that biopsy-derived a ult human tau is phosphorylated at 
most sites thought o be abnormally phosphorylated in PHF- 
tau. However, the authors also mention several observations 
that confirm the existence of differences in the phosphorylation 
state of normal brain tau and PHF-tau. They find a considera- 
ble quantitative difference in the degree of phosphorylation 
between PHF-tau and biopsy-derived brain tau and also de- 
scribe the selective specificity of the monoclonal ntibody AT 10 
(which binds to an unknown phosphorylation-dependent site 
on PHF-tau [40]) for PHF-tau in the absence of cross-reactivity 
with any of the normal biopsy- or autopsy-derived a ult or fetal 
brain tau preparations. Considerable differences in concentra- 
tions of highly phosphorylated tau is therefore still most likely 
the mechanism that may favor precipitation i to highly pro- 
tease resistant PHFs, which then can accumulate o intolerably 
high levels and cause neuronal dysfunction. 
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